Omori, Shota
Kenmotsu, Hirotsugu
Abe, Masato
Watanabe, Reiko
Sugino, Takashi
Kobayashi, Haruki
Nakashima, Kazuhisa
Wakuda, Kazushige
Ono, Akira
Taira, Tetsuhiko
Naito, Tateaki
Murakami, Haruyasu
Ohde, Yasuhisa
Endo, Masahiro
Akiyama, Yasuto
Nakajima, Takashi
Takahashi, Toshiaki
Article History
Received: 15 January 2018
Accepted: 8 June 2018
First Online: 15 June 2018
Compliance with ethical standards
:
: Dr. Shota Omori received personal fees from AstraZeneca, Boehriner Ingelheim, Chugai-Pharm, Taiho-Pharm, MSD and Ono-Pharma; Dr. Hirotsugu Kenmotsu received personal fees from AstraZeneca, Chugai-Pharma, Bristol-Myers, Boehriner Ingelheim, Eli Lilly, Kyowa Hakko Kirin, Taiho-Pharma, MSD and Ono-Pharma; Dr. Haruki Kobayashi received personal fees from Eli Lilly, and Taiho-Pharma; Dr. Kazuhisa Nakashima received personal fees from Eli Lilly, Taiho-Pharma, Mochida-Pharma and Ono-Pharma; Dr. Kazushige Wakuda received personal fees from Taiho-Pharma, Boehriner Ingelheim and Ono-Pharma; Dr. Akira Ono received personal fees from Chugai-Pharma, Takeda-Pharma and Taiho-Pharma; Dr. Tateaki Naito received personal fees from Ono-Pharma; Dr. Haruyasu Murakami received personal fees from AstraZeneca, Astellas, Bristol-Myers, Boehriner Ingelheim, Chugai-Pharma, Eli Lilly, Taiho-Pharma, MSD, Pfizer, Novartis and Ono-Pharma; Dr. Masahiro Endo received personal fees from Ono-Pharma; Dr. Toshiaki Takahashi received personal fees from AstraZeneca, Boehriner Ingelheim, Chugai-Pharma, Taiho-Pharma, MSD, Eli Lilly, Pfizer and Ono-Pharma, outside the submitted work. The other authors declare no conflict of interests.